Last update 08 May 2025

PF-06940434

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
CD51 x αvβ8
Action
antagonists, inhibitors
Mechanism
CD51 antagonists(Integrin alpha-V antagonists), αvβ8 inhibitors(Integrin αvβ8 inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid NeoplasmMetastatic Solid Tumor
Inactive Indication
Bile Duct NeoplasmsEndometrial CarcinomaEsophageal Carcinoma+ [8]
Originator Organization
Pfizer Inc.Pfizer Inc.
Active Organization
Pfizer Inc.Pfizer Inc.
Inactive Organization-
License Organization-
Drug Highest PhaseIND Approval
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with PF-06940434
NCT04152018
/ TerminatedPhase 1
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
100 Clinical Results associated with PF-06940434
Login to view more data
100 Translational Medicine associated with PF-06940434
Login to view more data
100 Patents (Medical) associated with PF-06940434
Login to view more data
100 Deals associated with PF-06940434
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 1
Australia
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Ovarian CancerPhase 1
United States
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Papillary Renal Cell CarcinomaPhase 1
Taiwan Province
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Papillary Renal Cell CarcinomaPhase 1
Australia
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Papillary Renal Cell CarcinomaPhase 1
United States
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Papillary Renal Cell CarcinomaPhase 1
Slovakia
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Transitional Cell CarcinomaPhase 1
United States
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Transitional Cell CarcinomaPhase 1
Slovakia
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Transitional Cell CarcinomaPhase 1
Taiwan Province
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Transitional Cell CarcinomaPhase 1
Australia
Pfizer Inc.Pfizer Inc.
13 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free